These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38761340)

  • 1. Pathological complete response with FOLFIRINOX therapy for recurrence of pancreatic acinar cell carcinoma.
    Teramatsu K; Fujimori N; Murakami M; Yasumori S; Matsumoto K; Nakata K; Nakamura M; Koga Y; Oda Y; Ogawa Y
    Clin J Gastroenterol; 2024 Aug; 17(4):776-781. PubMed ID: 38761340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of BRCA1-mutated giant pancreatic acinar cell carcinoma successfully treated with modified FOLFIRINOX therapy and radical resection.
    Watanabe T; Nagaoka Y; Kimura N; Fukasawa M; Shirai Y; Hirano K; Shibuya K; Yoshioka I; Hamashima T; Fujii T
    Clin J Gastroenterol; 2024 Oct; 17(5):970-975. PubMed ID: 38836973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: A case report.
    Uemura S; Maeda H; Tanioka N; Yamaguchi S; Munekage M; Kitagawa H; Namikawa T; Yamamoto S; Kohsaki T; Iguchi M; Uchida K; Hanazaki K
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1648. PubMed ID: 35668046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline BRCA1-Mutated Synchronous and Metachronous Pancreatic Acinar Cell Carcinoma With Long-Term Survival.
    Kubo T; Ikeda Y; Muramatu J; Ishikawa K; Yoshida M; Kukita K; Imamura M; Sugita S; Sakurai A; Takada K
    Cancer Rep (Hoboken); 2024 Aug; 7(8):e70007. PubMed ID: 39188100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathological complete response in a patient with metastatic pancreatic acinar cell carcinoma who received a chemotherapy regimen containing cisplatin and irinotecan.
    Maehira H; Iida H; Mori H; Nitta N; Tokuda A; Takebayashi K; Kaida S; Miyake T; Matsubara A; Tani M
    Clin J Gastroenterol; 2021 Dec; 14(6):1772-1778. PubMed ID: 34596871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic acinar cell carcinoma with bilateral ovarian metastases, panniculitis and polyarthritis treated with FOLFIRINOX chemotherapy regimen. A case report and review of the literature.
    Callata-Carhuapoma HR; Pato Cour E; Garcia-Paredes B; Fernandez RM; Mendoza Fernandez ML; Fernandez AM; De La Rosa CA; Sotelo Lezama MJ; Cabezas-Camarero S; Sastre Varela J
    Pancreatology; 2015; 15(4):440-4. PubMed ID: 25959244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
    Schneitler S; Kröpil P; Riemer J; Antoch G; Knoefel WT; Häussinger D; Graf D
    World J Gastroenterol; 2015 May; 21(20):6384-90. PubMed ID: 26034375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report.
    Schempf U; Sipos B; König C; Malek NP; Bitzer M; Plentz RR
    Z Gastroenterol; 2014 Feb; 52(2):200-3. PubMed ID: 24526405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature.
    Busch E; Werft W; Bougatf N; Hackert T; Jäger D; Springfeld C; Berger AK
    Pancreas; 2021 Mar; 50(3):300-305. PubMed ID: 33835959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
    Ghaneh P; Palmer D; Cicconi S; Jackson R; Halloran CM; Rawcliffe C; Sripadam R; Mukherjee S; Soonawalla Z; Wadsley J; Al-Mukhtar A; Dickson E; Graham J; Jiao L; Wasan HS; Tait IS; Prachalias A; Ross P; Valle JW; O'Reilly DA; Al-Sarireh B; Gwynne S; Ahmed I; Connolly K; Yim KL; Cunningham D; Armstrong T; Archer C; Roberts K; Ma YT; Springfeld C; Tjaden C; Hackert T; Büchler MW; Neoptolemos JP;
    Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):157-168. PubMed ID: 36521500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical resection of hepatic and rectal metastases of pancreatic acinar cell carcinoma (PACC): a case report.
    Ohara Y; Oda T; Enomoto T; Hisakura K; Akashi Y; Ogawa K; Owada Y; Domoto Y; Miyazaki Y; Shimomura O; Kurata M; Ohkohchi N
    World J Surg Oncol; 2018 Aug; 16(1):158. PubMed ID: 30075727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial.
    Labori KJ; Bratlie SO; Andersson B; Angelsen JH; Biörserud C; Björnsson B; Bringeland EA; Elander N; Garresori H; Grønbech JE; Haux J; Hemmingsson O; Liljefors MG; Myklebust TÅ; Nymo LS; Peltola K; Pfeiffer P; Sallinen V; Sandström P; Sparrelid E; Stenvold H; Søreide K; Tingstedt B; Verbeke C; Öhlund D; Klint L; Dueland S; Lassen K;
    Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):205-217. PubMed ID: 38237621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
    Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
    Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
    Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review.
    Matsubayashi H; Todaka A; Tsushima T; Kiyozumi Y; Harada R; Ishihara E; Higashigawa S; Ohike N; Sakamoto H; Sato J; Ishiwatari H; Sugiura T; Uesaka K
    Fam Cancer; 2024 Aug; 23(3):393-398. PubMed ID: 38733420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Surgical Resection of Metachronous Hepatic Metastasis from Pancreatic Acinar Cell Carcinoma after Total Pancreatectomy].
    Mishima T; Furukawa K; Shimizu H; Ohtsuka M; Kato A; Yoshitomi H; Takayashiki T; Kuboki S; Takano S; Okamura D; Suzuki D; Sakai N; Kagawa S; Miyazaki M
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2403-5. PubMed ID: 26805378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of pathologically complete response after preoperative chemotherapy in a pancreatic acinar cell carcinoma patient with portal vein tumor thrombosis.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Takayama Y; Shimizu K; Tokushige K; Egawa H; Yamamoto M
    Clin J Gastroenterol; 2022 Jun; 15(3):642-648. PubMed ID: 35013933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A case of liver metastasis of mixed acinar-endocrine carcinoma treated with various loco-regional cancer therapies].
    Nishii T; Amano R; Nakao S; Doi Y; Yamada N; Ohira M; Hirakawa K
    Gan To Kagaku Ryoho; 2008 Nov; 35(12):2126-8. PubMed ID: 19106545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin.
    Hall JC; Marlow LA; Mathias AC; Dawson LK; Durham WF; Meshaw KA; Mullin RJ; Synnott AJ; Small DL; Krishna M; von Hoff D; Schüler J; Hart SN; Couch FJ; Colon-Otero G; Copland JA
    J Transl Med; 2016 May; 14(1):129. PubMed ID: 27165126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.